EU/3/15/1529

About

On 28 July 2015, orphan designation (EU/3/15/1529) was granted by the European Commission to QRC Consultants Ltd., United Kingdom, for glycyl-L-2-methylprolyl-L-glutamic acid for the treatment of fragile X syndrome.

The sponsorship was transferred to DLRC Pharma Services Ltd, Ireland, in February 2019.

Key facts

Active substance
Glycyl-L-2-methylprolyl-L-glutamic acid
Disease / condition
Treatment of fragile X syndrome
Date of decision
28/07/2015
Outcome
Positive
Orphan decision number
EU/3/15/1529

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Dlrc Pharma Services Limited
Chesterfield House
Clonmannon
Ashford
Co. Wicklow
A67 WR29
Ireland
Tel. +353 40478808
E-mail: regulatory.submissions@dlrc.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating